Pamiparib is under clinical development by BeiGene and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pamiparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pamiparib overview
Pamiparib (Baihuize) is an anti-neoplastic agent. It is formulated as capsules for oral route of administration. Baihuize is indicated for the treatment of patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.
Pamiparib (BGB-290) is under development for the treatment of advanced or metastatic adenocarcinoma of the stomach or gastro esophageal junction, relapsed or refractory solid tumors including recurrent glioblastoma multiforme (GBM), cervical cancer, bile duct cancer, peripheral nerve sheath cancer, ovarian cancer, endometrial cancer, triple negative breast cancer, metastatic HR positive and HER2 negative breast cancer, non-squamous non-small cell lung cancer, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, leiomyosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, myxofibrosarcoma, primary peritoneal cancer, fallopian cancer, metastatic castration-resistant prostate cancer (mCRPC), high-grade glioma, low-grade glioma, small-cell lung cancer and pancreatic cancer. The drug candidate is administered orally. It targets the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP-1 and PARP-2).
It was also under development for gastric cancer and metastatic or unresectable renal cell carcinoma, colorectal cancer, transitional cell cancer (urothelial cell cancer), muscle invasive bladder cancer (MIBC), metastatic adenocarcinoma of the pancreas, cervical cancer, bile duct cancer (cholangiocarcinoma),endometrial cancer, ureter cancer, urethral cancer.
BeiGene overview
BeiGene is a biotechnology company. It specializes in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers Zanubrutinib, a small molecule inhibitor to treat various blood cancers and Sonrotoclax, a small molecule Bcl-2 inhibitor for treating chronic lymphocytic leukemia. BeiGene also provides Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. The company has operations in the US, Australia, Germany, Spain, Canada, Switzerland and Italy. BeiGene is headquartered in the Cayman Islands.
For a complete picture of Pamiparib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
